1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on March 12, 2025

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
INCY

Benzinga

a day ago

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
INCY

Benzinga

2 days ago

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
INCY

Zacks

2 days ago

INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
INCY

Zacks

2 days ago

LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

INCY

MT Newswires

2 days ago

Eli Lilly, Incyte Report Significant Hair Regrowth in Adolescents Treated With Baricitinib

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
INCY

PR Newswire

4 days ago

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
INCY

Business Wire

4 days ago

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

5 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

9 days ago

Incyte Insider Sold Shares Worth $1,042,136, According to a Recent SEC Filing

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?
INCY

Insider Monkey

11 days ago

Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
INCY

Business Wire

12 days ago

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

High Growth Tech Stocks to Watch in US Market February 2025
INCY

Simply Wall St.

12 days ago

High Growth Tech Stocks to Watch in US Market February 2025

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery
INCY

Insider Monkey

15 days ago

Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery

INCY

Argus Research

16 days ago

Analyst Report: Incyte Corp.

INCY

Argus Research

16 days ago

Market Digest: ALB, BAX, CHH, INCY, KBH, MCK, SO, HUBS, TRGP

Incyte and Genesis collaborate on small-molecule medicines
INCY

Pharmaceutical Technology

19 days ago

Incyte and Genesis collaborate on small-molecule medicines

INCY

MT Newswires

20 days ago

Incyte, Genesis Therapeutics Form AI-Centered Collaboration to Discover Small Molecule Medicines

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
INCY

Business Wire

20 days ago

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte Stock Sees Relative Strength Rating Rise To 71
INCY

Investor's Business Daily

22 days ago

Incyte Stock Sees Relative Strength Rating Rise To 71

Incyte to Present at Upcoming Investor Conferences
INCY

Business Wire

22 days ago

Incyte to Present at Upcoming Investor Conferences

3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value
INCY

Simply Wall St.

23 days ago

3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value

INCY

MT Newswires

a month ago

JPMorgan Adjusts Incyte Price Target to $70 From $75, Maintains Neutral Rating

INCY

Morningstar Research

a month ago

Analyst Report: Incyte Corporation

INCY

MT Newswires

a month ago

UBS Cuts Price Target on Incyte to $69 From $77, Keeps Neutral Rating

INCY

MT Newswires

a month ago

Citigroup Adjusts Price Target on Incyte to $88 From $97, Maintains Buy Rating

INCY

MT Newswires

a month ago

Stifel Adjusts Price Target on Incyte to $77 From $75, Maintains Hold Rating

INCY

MT Newswires

a month ago

TD Cowen Adjusts Price Target on Incyte to $88 From $86, Maintains Buy Rating

INCY

MT Newswires

a month ago

Jefferies Adjusts Price Target on Incyte to $81 From $84, Maintains Buy Rating

INCY

MT Newswires

a month ago

RBC Trims Price Target on Incyte to $68 From $70, Keeps Sector Perform Rating

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
INCY

Simply Wall St.

a month ago

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
INCY

GuruFocus.com

a month ago

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

INCY

Argus Research

a month ago

Weekly Stock List

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4
INCY

StockStory

a month ago

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4

INCY

Associated Press Finance

a month ago

Incyte: Q4 Earnings Snapshot

INCY

MT Newswires

a month ago

Incyte' Q4 Adjusted Earnings, Revenue Rise

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
INCY

Business Wire

a month ago

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
INCY

StockStory

a month ago

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

a month ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Incyte to $75 From $71

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
INCY

Zacks

a month ago

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
INCY

Zacks

a month ago

Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY

Zacks

a month ago

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

Incyte (INCY) Earnings Expected to Grow: Should You Buy?
INCY

Zacks

a month ago

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Exploring High Growth Tech Stocks In January 2025
INCY

Simply Wall St.

a month ago

Exploring High Growth Tech Stocks In January 2025

INCY

MT Newswires

2 months ago

RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
INCY

Business Wire

2 months ago

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
INCY

Zacks

2 months ago

Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

INCY

MT Newswires

2 months ago

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
INCY

PR Newswire

2 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

JP Morgan 2025: Incyte expects period of ‘defining catalysts’
INCY

Pharmaceutical Technology

2 months ago

JP Morgan 2025: Incyte expects period of ‘defining catalysts’

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
INCY

Zacks

2 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

5 Biotech Stocks Worth Adding to Your Portfolio in 2025
INCY

Zacks

2 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
INCY

Zacks

2 months ago

Has Incyte (INCY) Outpaced Other Medical Stocks This Year?

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
INCY

Business Wire

2 months ago

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

INCY vs. VRTX: Which Stock Is the Better Value Option?
INCY

Zacks

2 months ago

INCY vs. VRTX: Which Stock Is the Better Value Option?

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

2 months ago

RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating

Exploring Three High Growth Tech Stocks in the United States
INCY

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks in the United States

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
INCY

Zacks

3 months ago

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

Incyte price target raised to $70 from $68 at Wells Fargo
INCY

TipRanks

3 months ago

Incyte price target raised to $70 from $68 at Wells Fargo

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
INCY

Zacks

3 months ago

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

INCY

MT Newswires

3 months ago

Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating

INCY

MT Newswires

3 months ago

UBS Initiates Coverage on Incyte With Neutral Rating, $77 Price Target

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

3 months ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

3 months ago

Leerink Adjusts Price Target on Incyte to $100 From $87, Maintains Outperform Rating

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
INCY

Clinical Trials Arena

3 months ago

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma
INCY

Clinical Trials Arena

3 months ago

ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
INCY

Zacks

3 months ago

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

INCY

MT Newswires

3 months ago

Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

3 months ago

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

INCY

Morningstar Research

3 months ago

Analyst Report: Incyte Corporation

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
INCY

Zacks

3 months ago

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals

EXEL or INCY: Which Is the Better Value Stock Right Now?
INCY

Zacks

3 months ago

EXEL or INCY: Which Is the Better Value Stock Right Now?

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
INCY

Business Wire

3 months ago

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

3 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

3 months ago

Incyte Insider Sold Shares Worth $455,544, According to a Recent SEC Filing

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
INCY

Zacks

3 months ago

Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
INCY

Zacks

3 months ago

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

Exploring 3 High Growth Tech Stocks in the United States
INCY

Simply Wall St.

3 months ago

Exploring 3 High Growth Tech Stocks in the United States

Incyte Announces Updated Presentation Time for Upcoming Investor Conference
INCY

Business Wire

3 months ago

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
INCY

Business Wire

4 months ago

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

INCY

MT Newswires

4 months ago

TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
INCY

Insider Monkey

4 months ago

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
INCY

Zacks

4 months ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

INCY

Morningstar Research

4 months ago

Analyst Report: Incyte Corporation

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
INCY

MT Newswires

4 months ago

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict

INCY

MT Newswires

4 months ago

Equity Markets Close Mixed Ahead of Nvidia Earnings

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
INCY

Investopedia

4 months ago

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing

INCY

MT Newswires

4 months ago

Sector Update: Health Care Stocks Decline

INCY

MT Newswires

4 months ago

Top Midday Decliners

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
INCY

MT Newswires

4 months ago

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict

INCY

MT Newswires

4 months ago

Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
INCY

Zacks

4 months ago

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
INCY

Investor's Business Daily

4 months ago

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

INCY

MT Newswires

4 months ago

RBC Cuts Price Target on Incyte to $74 From $80, Keeps Sector Perform Rating

INCY

Morningstar Research

4 months ago

Analyst Report: Incyte Corporation

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
INCY

Business Wire

4 months ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
INCY

Insider Monkey

4 months ago

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
INCY

Insider Monkey

4 months ago

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects

INCY

Morningstar Research

4 months ago

Analyst Report: Incyte Corporation

Share on Social Networks: